Eighteen patients (men = 14; women = 4) with natural killer (NK)/T-cell lymphomas (CR1, N = 9; CR2, N = 7; PR, N = 1; progressive disease, N = 1) undergoing allogeneic haematopoietic SCT (HSCT) (myeloablative, N = 14; reduced intensity, N = 4) were analyzed. With a median follow-up of 20.5 months, the 5-year OS was 57% and 5-year EFS was 51%. The use of the SMILE regimen pre-HSCT was the most important positive prognostic indicator, resulting in significantly superior OS and EFS (P o 0.01). Acute GVHD had a significant negative impact on OS (P = 0.03). CR1 and CR2 patients had similar survivals, but all patients who were not transplanted in remission died. Chronic GVHD, International Prognostic Index, disease stage, primary sites of involvement, conditioning regimen and source of HSC did not affect survival. Although allogeneic HSCT leads to reasonable survival for NK/T-cell lymphoma patients, results need to be compared with those in patients receiving L-asparaginase-containing regimens. Novel prognostic models incorporating biomarkers, such as circulating EBV DNA, are needed to identify high-risk patients who may benefit from allogeneic HSCT.
INTRODUCTION
Natural killer (NK)/T-cell lymphoma is a very rare disease. 1 Occurring worldwide, it has a predilection for Asian and South American populations. 2, 3 Most of the cases are derived putatively from NK cells, without T-cell receptor (TCR) gene rearrangement. A minority may be of bona fide T-cell lineage, with clonal TCR gene rearrangement. 1 There is an invariable association with EBV infection. 3 Clinically, it is classified into 'nasal' or 'non-nasal' types. In the nasal type, the primary sites include the nose or nasopharynx, although the paranasal sinuses, tonsils, Waldeyer's ring and oropharynx may also be affected. 2 In about 20% of patients, the tumours may arise from the skin, gastrointestinal tract or testis without clinically evident nasal involvement. 2, 3 However, with sensitive radiological imaging such as positron emission tomography computed tomography, most 'non-nasal' cases can in fact be shown to have occult nasal involvement. 3, 4 For early stage (I/II) disease, conventional chemotherapeutic regimens designed for aggressive B-cell lymphomas, such as CHOP (CY, adriamycin, vincristine, prednisone) or CHOP-like regimens, give unsatisfactory results. 3, 5 Recent studies of L-asparaginase-containing regimens combined with radiotherapy have reported overall response rates of about 90%, with CR in 70-80% of cases. [6] [7] [8] The 2-year PFS and OS were 80-86% and 86-89%, respectively. [6] [7] [8] However, in advanced-stage or relapsed/ refractory diseases, the treatment outcome is still unfavourable. In a phase II study of SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide) in stage IV and relapsed/ refractory diseases, the overall response rate was 79%, with CR in 45% of cases. 9 The 1 year PFS and OS were 53% and 55%, respectively. High-dose chemotherapy with haematopoietic SCT (HSCT) has been used to improve the outcome of NK/T-cell lymphoma. However, autologous HSCT for early-stage NK/T-cell lymphoma does not confer additional benefit compared with combined chemotherapy and radiotherapy. 10 In advanced-stage disease, the role of autologous HSCT is debatable, because its results are either comparable with or in fact inferior to L-asparaginase-containing regimens. 6, 10 Owing to a putative graft-versus-lymphoma effect, allogeneic HSCT has also been explored, especially in poor-risk patients with advanced-stage disease. [11] [12] [13] In an earlier study of allogeneic HSCT in 28 patients with CD56-positive neoplasms, which included 22 patients with NK/T-cell lymphoma, the 2-year OS and PFS were 40% and 34%, with a TRM of 20-30% depending on the conditioning regimen. 11 Unfortunately, results of patients with NK/T-cell lymphomas were not separately described, and the survivals were not spectacular in comparison with L-asparaginasecontaining regimens. In another study of 12 patients with NK/T-cell lymphomas treated with allogeneic HSCT, the 3-year OS and PFS were 55 and 53%, with a TRM of 8%. 13 These survivals appeared to be only comparable with those from the use of L-asparginase-containing regimens.
With the advent of L-asparaginase-containing regimens as treatment for NK/T-cell lymphoma, the role of allogeneic HSCT in these patients should be reappraised. To address this issue, we conducted a retrospective analysis to examine the use and outcome of allogeneic HSCT in NK/T-cell lymphoma patients.
MATERIALS AND METHODS Patients
Four tertiary referral centres specialized in the management of NK/T-cell malignancies participated in this retrospective analysis. According to the Asia Lymphoma Study Group proposed algorithm, allogeneic HSCT was considered for patients with NK/T-cell lymphoma if they satisfied the following criteria: age o60 years, stage IV disease with BM involvement at first CR1 or chemotherapy-sensitive relapsed/refractory disease and suitable HSC donors available.
Conditioning regimens
Both myeloablative and reduced-intensity conditioning regimens were used. For myeloablative conditioning, they were based primarily on highdose BU, TBI or combination of CY, BCNU and etoposide. Combination of fludarabine and melphalan was used in patients receiving reducedintensity conditioning HSCT.
Statistical analysis
Differences between categorical variables were analyzed by Χ 2 -test. Continuous variables were analyzed by independent two sample t-test. Analysis of OS and EFS was conducted by the Kaplan-Meier method. Two-tailed P-values of less than 0.05 were taken as significant. All tests were performed with the SPSS 15.0 software package (Chicago, IL, USA).
RESULTS

Patients
Eighteen patients (14 men; 4 women) were studied ( Table 1 ). The median age was 40.5 years. Most of the patients had advancedstage (stage III/IV) disease (74%). Most patients (74%) had received SMILE for induction of remission before HSCT. The majority of patients (89%) were in CR (CR1, N = 9; CR2, N = 7) before HSCT. For patients transplanted at CR1, the initial chemotherapeutic protocols were CHOP-like regimens (N = 5) and SMILE (N = 4). For patients transplanted at CR2, the initial treatment protocols were CHOP-like regimens (N = 5), radiotherapy alone (N = 1) and SMILE (N = 1). At first relapse, all cases were treated with SMILE and achieved CR2. Conditioning regimens were myeloablative in 78% of cases.
HSCT outcome Acute GVHD developed in nine patients (grade 1-2: N = 7; grade 3-4: N = 2), which responded to treatment in all cases. Four patients developed chronic mucocutaneous GVHD (mild: N = 3; severe: N = 1), which was controlled with immunosuppressants. At a median follow-up of 20.5 (1.6-65) months, relapse occurred in five patients, with two of them dying from disease progression, and three salvaged with chemotherapy (two were alive at follow-up 1 and 31 months after salvage therapy, but one died of pneumonia at 2 months). Another four patients died of infection and one patient committed suicide.
Survivals
The 5-year OS was 57%, with the median survival not reached. The 5-year EFS was 51%. The survival curves appeared to have plateaued after 20 months (Figures 1a and b) .
Prognostic indicators Univariate analysis showed that patients who had received SMILE before HSCT had significantly better OS and EFS (median OS and EFS not reached) than patients treated with other regimens (median OS and EFS were 6.7 and 2.8 months, respectively; P o0.01) (Figures 1c and d) . The status of the remission (CR1 vs CR2) had no impact on survivals (Figure 1e ). The development of acute GVHD had a significantly negative impact on OS (Figure 1f Allogeneic HSCT in NK/T-cell lymphoma E Tse et al (myeloablative vs non-myeloablative) and source of HSC (BM vs peripheral blood) had no significant impact on survivals. On multivariate analysis, the use of SMILE chemotherapy pre-HSCT still remained the only significant factor impacting on EFS (P = 0.03), and showed a trend toward impacting on OS (P = 0.07). Acute GVHD was no longer a significant factor for OS (P = 0.25) and ESF (P = 0.8).
DISCUSSIONS
To date, this report is the largest study that focused exclusively on allogeneic HSCT for extranodal NK/T-cell lymphoma. More importantly, it is also the first study that examined HSCT in patients treated with SMILE, now considered a standard regimen for advanced-stage or relapsed/refractory NK/T-cell lymphoma. 3 The outcome in our patients was encouraging (5-year EFS and OS at 51 and 57% respectively). Results from other studies involving smaller numbers of NK/T-cell lymphoma patients treated with allogeneic HSCT are summarized in Table 2 . Two studies were conducted before L-asparaginse-containing regimens were used, 11, 14 whereas two studies contained some patients treated with L-asparaginase-containing regimens. 12, 13 Owing to the heterogeneity and small numbers of patients involved, most studies only stressed the feasibility of allogeneic HSCT.
There were several interesting observations from this analysis. First, patients who received SMILE as induction or salvage chemotherapy prior to allogeneic HSCT had a significantly better outcome than those receiving non-L-asparaginase-containing regimen. In our analysis, the number of patients not receiving SMILE pre-HSCT was relatively small compared with those receiving SMILE. This limitation was due to SMILE being considered a standard regimen for patients with NK/T-cell lymphoma in most centres, so that fewer and fewer patients would receive non-SMILE induction protocols. To further explore this point, a comparison of our results with two previously published studies of NK/T-cell lymphoma patients undergoing allogeneic HSCT, where survival data were provided, might be informative (Table 2 ). In the study by Murashige et al., 11 in which patients did not receive L-asparaginase-containing regimens, the 2-year PFS and OS were only 34 and 40%. However, in the study by Ennishi et al., 13 in which 42% of patients had received L-asparaginase-containing regimens before HSCT, the 3-year PFS and OS were 53 and 55%, which were comparable with our results.These observations together with ours might reflect a better quality, or deeper, remission and disease control achieved by SMILE or L-asparaginase-containing protocols as compared with other regimens. It is also consistent with the notion that the presence of residual disease at the time of HSCT is associated with a poor outcome.
Occurrence of the lymphoma primarily in non-nasal sites has been considered to be a poor prognostic indicator when conventional chemotherapy regimens were used. 2 With the SMILE regimen, it has been shown that the primary site of lymphoma no longer has any impact on outcome. 6 In this study, because the majority of patients had received SMILE before HSCT, the primary site also did not appear to impact on survival. This observation again suggested that with appropriate cytoreduction, the primary presentation site in NK/T-cell lymphoma had no significant clinical implication.
Attaining a remission has been found to be a significant factor impacting on the outcome after allogeneic HSCT in NK/T-cell lymphoma patients. 10 In this study, the majority of patients were transplanted in CR1 or CR2. Interestingly, CR1 and CR2 patients had comparable survivals. Only two patients were transplanted while not in remission, and both died. Hence, obtaining a remission is important before transplantation. Whether the quality or depth of remission, as determined by sensitive tumour biomarkers such as circulating EBV DNA, 15 may impact on survival will need to be determined.
Allogeneic HSCT remains a potentially curative option for patients with advanced-stage or relapsed/refractory NK/T-cell lymphoma. However, its use in patients treated with L-asparaginase-containing regimens should be carefully evaluated; in view of the short-and long-term toxicities of allogeneic HSCT, as well as the very good results achieved by SMILE or similar regimens. Given that the CR rate of using SMILE in relapsed/ refractory patients is very high, 6, 9 and that CR1 and CR2 patients fare similarly after allogeneic HSCT, frontline allogeneic HSCT for patients in CR1 does not seem justifiable. Furthermore, patients in CR1 induced by SMILE had been shown to have an estimated 4-year disease-free survival of 60%. 6 For relapsed patients achieving CR2 induced by SMILE, a 4-year disease-free survival of 68.2% was achieved. 6 Hence, HSCT may not be necessary for more than half of the patients in CR1 and CR2 induced by SMILE. Therefore, allogeneic HSCT should conceivably be reserved for CR1/CR2 patients who are at high risks of relapse.
In conclusion, with evolving strategies for more effective treatment of NK/T-cell lymphomas, the role of allogeneic HSCT in NK/T-cell lymphoma must be strictly evaluated. Recently, it has been shown that failure to achieve undetectable circulating EBV DNA after one to two courses of SMILE portends a very poor prognosis. Indicates that the data included patients with other natural killer cell neoplasms in the study.
